Empowered Patient Podcast Healing Chronic Complex Wounds with Perinatal Tissue Allografts with Jason Matuszewski and Andrew Van Vurst BioStem Technologies
Jason Matuszewski, Chief Executive Officer and Chairman of the Board, and Andrew Van Vurst, Chief Operating Officer of BioStem Technologies have a vision to change the paradigm on the use of perinatal tissue for advanced wound care. Their initial target is complex wounds in the lower extremity region, specifically focusing on diabetic foot ulcers, venous ulcers, and pressure ulcers using a perinatal tissue allograft to promote healing.
Jason explains, "In general, non-healing and complex wounds share similar characteristics, high levels of protease, elevated inflammatory markers, low growth factor activity, and reduced cellular proliferation."
"Chronic non-healing wounds are wounds that have failed to progress through a timely sequence of repair or proceed through the wound healing process without restoring anatomic or functional results. A large amount of these wounds add a huge burden on cost. Specifically, our initial market, Medicare patients, things of that nature, add up to the tune of almost $25 billion spent on healthcare systems treating these complex wound types."
Andrew elaborates, "We've identified a process that we've acquired some IP around called BioRetain. Our goal with these tissues to set ourselves apart is not only to act as a protective barrier covering for the wound and the wound environment to create a healing environment but also to retain as much of the actual structural tissue components and biologic tissue components within the donated tissue we receive."
@BSEM_Tech #BioStem #WoundHealing #ComplexWounds #SkinRegeneration #RegenerativeMedicine